Anti-Diabetes Drugs - Malta

Malta

The revenue in the Anti-Diabetes Drugs market in Malta is forecasted to reach US$10.60m in 2024.
It is expected to exhibit an annual growth rate (CAGR 2024-2029) of 8.03%, leading to a market volume of US$15.60m by 2029.
When compared globally, United States is projected to generate the highest revenue, amounting to US$37,840.00m in 2024.
Malta's pharmaceutical market is experiencing a rising demand for innovative anti-diabetes drugs due to the increasing prevalence of diabetes in the country.

Key regions: India, Australia, Italy, Europe, Brazil

Market

Region

Region comparison

Currency

Analyst Opinion

The demand for Anti-Diabetes Drugs in Malta has been increasing over the years due to the rise in the number of people diagnosed with diabetes.

Customer preferences: The Maltese population prefers oral anti-diabetic drugs over other types of drugs due to their convenience and ease of use. Patients prefer drugs that are effective and have minimal side effects.

Trends in the market: The Anti-Diabetes Drugs market in Malta has been growing due to the increase in the prevalence of diabetes. The market has been witnessing a shift towards generic drugs due to their affordability. The market has also witnessed an increase in the demand for combination drugs that offer a more comprehensive approach to diabetes management.

Local special circumstances: Malta has a high prevalence of diabetes due to its aging population, unhealthy eating habits, and sedentary lifestyle. The country has a public healthcare system that provides free diabetes treatment to its citizens. This has led to an increase in the demand for anti-diabetic drugs in the country.

Underlying macroeconomic factors: The Maltese economy has been growing steadily over the years, leading to an increase in the disposable income of its citizens. This has led to an increase in the demand for healthcare services, including diabetes management. The government has also been investing in the healthcare sector, leading to an increase in the availability of anti-diabetic drugs in the country.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.